menu

HBV

Featured Resources

Podcasts

cardImg

Optimizing Clinical Pathways to Achieve Functional Cure in CHB

06/03/2026

In this educational podcast, Paul Kwo, MD discusses how the goals of hepatitis B treatment are changing and what the future may look like for people living with chronic hepatitis B. While current medications do an excellent job of controlling the virus, most patients still need to stay on treatment long term. Dr. Kwo explains the growing focus on achieving a “functional cure,” which means losing the hepatitis B surface antigen—a key milestone that may allow some patients to eventually stop treatment and further reduce their risk of serious liver complications.

Throughout the presentation, Dr. Kwo reviews the benefits of today's hepatitis B therapies, including their ability to keep the virus under control and lower the risk of liver damage. He also discusses why achieving a functional cure is important, not only for reducing the risk of liver cancer but also for improving quality of life and helping patients feel less burdened by their disease.

The video also explores new treatment approaches being studied, how healthcare providers monitor patients over time, and what factors may help identify people who could benefit from future therapies. As hepatitis B research continues to advance, Dr. Kwo shares his perspective on how these developments may bring patients closer than ever to achieving long-term disease control and, potentially, a functional cure.
cardImg

Insights From 2025 EASL & AASLD Chronic Hepatitis B Guidelines

05/12/2026

Dr. Anthony Martinez, Medical Director of Hepatology at the University at Buffalo and Erie County Medical Center, discusses the evolving landscape of chronic hepatitis B management and the shift from viral suppression to precision immune control. In this expert overview, he highlights the latest 2025 AASLD and EASL guideline updates and explains how quantitative hepatitis B surface antigen (qHBsAg) testing is changing treatment decisions, particularly for hepatitis B e antigen-negative patients.

This discussion explores when clinicians may consider stopping nucleos(t)ide analog therapy, the importance of the ≤100 IU/mL qHBsAg threshold, and why treatment discontinuation should never be considered in patients with cirrhosis or unreliable follow-up. Dr. Martinez also reviews how qHBsAg trends can help personalize monitoring, HCC surveillance, and treatment timing while supporting the pursuit of functional cure.

Using a real-world clinical scenario, he examines emerging strategies aimed at antigen reduction, including PEG interferon add-on therapy and novel functional cure approaches. This video is ideal for hepatologists, gastroenterologists, and advanced practice providers looking to stay current on modern hepatitis B management, functional cure strategies, and the growing role of immune-informed decision-making.
cardImg

Viral Hepatitis – What’s Changing?

04/17/2025

Join Dr. Paul Kwo, from Stanford Medicine, and Dr. Tatyana Kushner, from Weill Cornell Medicine, for an insightful discussion on the evolving landscape of viral hepatitis, with a focus on hepatitis B, C, and delta hepatitis. This expert-led conversation explores the path toward hepatitis elimination by 2030, highlighting the latest advances in functional cure strategies for hepatitis B—including antisense oligonucleotides, capsid inhibitors, and immune modulators—and how they may redefine long-term disease management. The session also addresses the challenges of expanding hepatitis C treatment access to underserved and high-risk populations, the potential of long-acting injectables, and the need for simplified, rapid test-and-treat models. The dialogue concludes with a thoughtful analysis of delta hepatitis screening, global treatment guidelines, and the realistic timeline for achieving a functional cure for hepatitis B. Whether you’re a hepatologist, infectious disease specialist, or public health professional, this conversation offers critical insights into the next era of viral hepatitis care and innovation.
View All Podcasts arrow

Abstract Library

Unlocking Boundless Knowledge Through Abstracts

View All Modules arrow
alcbimg

Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction.

07/01/2026

Tak Kwon Yong (KY);Kim Seok Hwan (SH);Song Myeong Jun (MJ)

alcbimg

Applying the Baveno VII Criteria for Variceal Screening to Reduce Endoscopy Costs and Risks to Patients in an Australian Referral Centre.

06/11/2026

Thio Joel (J);Mansoor Matthew (M);Gluch Alexander (A);Shahzad Asif (A)

alcbimg

Infectious diseases, and risk factors among refugees, people living in underserved neighbourhoods, migrant, and internally displaced populations: a systematic review.

07/11/2026

Nyasulu Fingani Annie Mphande (FAM);Milanzi Edith Bridget (EB);Kachipedzu Amos (A);Ngunguni Shareef (S);Chisambo Anastanzia Nancy (AN);Ibrahim Edna (E);Majeza Ndaziona Immaculate (NI);Msiska Manley Kamija (MK);Samikwa Lyson (L);Msefula Chisomo Lawrence (CL)